Notebook

What stem cell initiative?California's Proposition 71 on the Nov. 2 ballot would create a $3 billion California Institute for Regenerative Medicine based on stem cell research. Supporters have raised about $15 million, aired thousands of television ads, and garnered media attention across the United States. But ask a Californian about the local buzz on the ballot initiative and the likely answer will be, "I haven't heard anyone talking about it."Karen Grant, who works at the Good Ol' Boys Saloon

Written byAndrew Holtz
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

California's Proposition 71 on the Nov. 2 ballot would create a $3 billion California Institute for Regenerative Medicine based on stem cell research. Supporters have raised about $15 million, aired thousands of television ads, and garnered media attention across the United States. But ask a Californian about the local buzz on the ballot initiative and the likely answer will be, "I haven't heard anyone talking about it."

Karen Grant, who works at the Good Ol' Boys Saloon & Sports Bar, just down the road from Disneyland in Anaheim, says the only initiative that's a "big deal" for her customers is one to expand casino gambling. "I haven't heard anybody mention it," Grant says of the stem cell research initiative. When asked whether any customers would like to share their thoughts, Grant calls out in the bar: "Anybody here have an opinion about the stem cell initiative?" The response: "Nope."

There ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies